Scholar Rock Holding Corp SRRK

Healthcare Biotechnology

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.

NDAQ:SRRK - Post by User

Scholar Rock Holding Corp

<< Previous

Bullboard Posts

Next >>

Post by TurbWealth35on Nov 26, 2024 7:33am

16 Views

Post# 36330666

Bullish Breakout in $SRRK and Opportunity in $MYNZ

$SRRK broke through the $35 channel, signaling strong bullish momentum. With volume confirming the move, it’s eyeing August 2021 levels near $45. Meanwhile, $MYNZ’s partnership news hasn’t fully played out yet, making it a great entry at current prices.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program